← board
SNYNF
distress 3/10 · well-funded / low risk$84.95-1%today-19% from 52w high
Revenue
$11244M
Liquidity
$12155M
Runway
—
Shares 1y
0%
Price & events
-10.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
-2.4%
1W
+1.9%
1M
-8.1%
3M
-8.7%
6M
-12.8%
1Y
-10.3%
2Y
-1.7%
5Y
+7.6%
All
Overview
- Market Cap
- $103.59B
- Enterprise Value
- $110.34B
- Volume
- 214
- 52 Week Range
- $81.29 – $105
- Total Shares
- 1.22B
- Float Shares
- 1.09B
- % Held by Insiders
- 10.26%
- % Held by Institutions
- 42.84%
- RVOL
- 0.02x
- Beta
- 0.28
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (5)
- FEXINIDAZOLEFEXINIDAZOLE2021 · Prescription
- RENVELASEVELAMER CARBONATE2007 · Prescription
- HECTOROLDOXERCALCIFEROL2000 · Discontinued
- HECTOROLDOXERCALCIFEROL1999 · Discontinued
- FLOMAXTAMSULOSIN HYDROCHLORIDE1997 · Discontinued
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.